Industry Supported Sessions
All conference participants may enter the industry sessions.
No additional registration is required.
Wednesday, 19 February 2020 | 14:30-16:00 | Madrid Hall
14:30-14:50 Value of Blinded CGM and Overview of Envision™ Pro
Robert Vigersky (USA)
14:50-15:10 ADJUST Study Review
Rogério Ribeiro (Portugal)
15:10-15:30 Cost-Effectiveness Analysis of the ADJUST Study
Simona de Portu (Switzerland)
15:30-15:50 Envision™ Pro Early Insights
Speakers from Pilot Hospitals
15:50-16:00 Close & Additional Envision™ Pro Events at ATTD
Robert Vigersky (USA)
CHAIR: Tadej Battelino (Slovenia)
Wednesday, 19 February 2020 | 14:30-16:00 | Rome Hall
14:30 – 14:50
The Evolving Landscape of Sensor-Based Technology for Optimizing Clinical Outcomes Across the Comprehensive Spectrum of Type 2 and Type 1 Diabetes Care
A Technology-to-Therapy Roadmap for Clinical Success in Diabetes
Tadej Battelino (Slovenia)
14:50 – 15:20
Translating Landmark and Meta-Analyses Trials in CGM to the Front Lines of Diabetes Care: Focus on the Role of Sensor-Based Technology to Improve Time in Range and Interpretation of Ambulatory Glucose Profiles
The Evidence for CGM to Improve Safety, Outcomes, HbA1c Target Goal Attainment and Patient Satisfaction in Persons with Diabetes
Richard Bergenstal (USA)
15:20 – 15:50
Real World, Interactive Case Management Sessions with the Faculty: Clinical Decision-Making Using Sensor-Based Glucose Monitoring Technology Across the Full Spectrum of Diabetes Care
Practical Application of Technology-Directed Treatments to Optimize Management of Persons with Diabetes: From Information to Intervention
Ramzi Ajjan (UK)
15:50 – 15:55
Program Chair’s Summary and Vision Statement
The Foundational Role of Sensor-Based Glucose Monitoring Technology—How Should Clinicians and Patients Collaborate and Use Sensor-Based Technology to Improve Diabetes Care?
Tadej Battelino (Slovenia)
15:55 – 16:00
Interactive Q&A Session
Tadej Battelino (Slovenia)
Wednesday, 19 February 2020 |16:15-17:45 | Paris Hall
16:15- 16:30 The MiniMed™ 670G System
Ohad Cohen (Israel)
16:30- 16:45 From MDI to the MiniMed™ 670G System: The Clinical Evidence
Goran Petrovski (Qatar)
16:45-17:45 From MDI to the MiniMed™ 670G System: The Practice
Goran Petrovski (Qatar)
Chair: Tadej Battelino (Slovenia)
Thursday, 20 February 2020 | 10:30-12:00 | Auditorium A
10:30-10:50 Evidence Based Call for Technology Access: Learnings from the SWEET Registry
Tadej Battelino (Slovenia)
10:50-11:10 Real Life Performance of the MiniMed™ 670G System
Ohad Cohen (Israel)
11:10-11:30 Successfully Managing Exercise with the MiniMed™ 670G System: Clinical Evidence
David O’Neal (Australia)
11:30-11:50 Improving Patient Experience & Outcomes with Advanced Algorithms
Robert Vigersky (USA), Tadej Battelino (Slovenia), David O’Neal (Australia) and Martin De Bock (New Zealand)
11:50-12:00 Q&A Session
Tadej Battelino (Slovenia)
Thursday, 20 February 2020 |13:00-14:30 | Paris Hall
13:00-13:15 The MiniMed™ 670G System
Ohad Cohen (Israel)
13:15-13:30 From MDI to the MiniMed™ 670G System: The Clinical Evidence
Goran Petrovski (Qatar)
13:30-14:30 From MDI to the MiniMed™ 670G System: The Practice
Goran Petrovski (Qatar)
CHAIR: Keri Leone (USA)
Thursday, 20 February 2020, | 13:00-14:30 | Rome Hall
13:00 - 13:50 Advances in Automated Insulin Delivery and Advanced Hybrid Closed Loops with the Dexcom G6
Boris Kovatchev (USA), Roman Hovorka (UK), Eric Renard (France), Pierre Yves Benhamou (France) and Greg Forlenza (USA).
13:50 - 14:10 Dexcom Real Time CGM In Pregnancy: Updates in Clinical Research and Practical Application
Carol Levy (USA) and Eyal Dassau (USA)
14:10 - 14:30 Updates and Advances with Dexcom CGM Technology
Jake Leach (USA)
CHAIRS: John Pickup (UK)
Thursday, 20 February 2020 | 15:00 - 16:30 | Auditorium A
15:00-15:02 Welcome/Agenda
John Pickup (UK)
15:02-15:17 Innovation in User Experience with the Omnipod DASH™ System
Eric Benjamin (US)
15:17-15:35 Real world benefits of the Omnipod DASH™ System
Grazia Aleppo (USA)
15:35-15:40 Audience Q&A
15:40-16:10 Debate: Tubeless, The Type of Pump Matters
John Pickup (UK), Emma Wilmot (UK) and Pratik Choudhary (UK)
16:10-16:25 Omnipod® into the Future: Latest Clinical Findings
Greg Forlenza (USA)
16:25-16:29 Audience Q&A
16:29-16:30 Summary/Close/Thank you
John Pickup (UK)
Moderator: Steph Habif (USA)
Thursday, 20 February 2020 | 16:40 - 18:00 | London Hall
16:40-16:50 Introductions
16:50-17:10 Satisfaction and Reduction in Diabetes Burden with Basal-IQ Predictive Low Glucose Suspend
Laurel Messer (USA)
17:10-17:30 Automated bolus and basal modulation with Control-IQ leads to better glycemic outcomes in adults and adolescents.
Marc D. Breton (USA)
17:30-17:50 Impact of Control-IQ on glycemic control for school age children with T1D
R. Paul Wadwa (USA)
17:50-18:00 Questions
CHAIR: Chantal Mathieu (Belgium)
Friday, 21 February 2020, | 08:00-08:45 | Madrid Hall
08:00 - 08:05 Welcome and Introduction
Chantal Mathieu (Belgium)
08:05 - 08:25 Caregiver Experience of Severe Hypoglycaemia and the Drive for Innovative Glucagon
Robert Oringer (USA)
08:25 - 08:40 BAQSIMI Clinical Profile and Product Demonstration
Chantal Mathieu (Belgium)
08:40 - 08:45 Closing Remarks
Chantal Mathieu (Belgium)
BAQSIMI is authorized by the European health authorities for the treatment of severe Hypoglycaemia. Approval for price/reimbursement by the National Health System is pending in Spain
CHAIR: Julio Rosenstock (USA)
Friday, 21 February 2020, | 09:00-10:00 | Madrid Hall
09:00–09:10 Innovation in therapies for T2D
Julio Rosenstock (USA)
09:10–09:20 Navigating through the treatment options after metformin
Peter Rossing (Denmark)
09:20–09:30 The evolving incretin landscape
Julio Rosenstock (USA)
09:30–09:40 The vulnerable patient: investigating semaglutide in renal impairment and late stage disease
Ofri Mosenzon (Israel)
09:40–09:50 Cardiovascular outcomes with semaglutide: current and future insights
Mansoor Husain (Canada)
09:50–10:00 Q & A / Panel discussion
All
CHAIR: Keri Leone (USA)
Friday, 21 February 2020, | 09:00-10:00 | Rome Hall
09:00–09:20 Dexcom Clarity and Dexcom G6 Features: Correlational Trends in Glycemic Improvement
Robert Dowd (USA)
09:20–09:40 Patient Engagement with Dexcom G6: Does Use of More Features Lead to Better Patient Outcomes?
Mark Derdzinski (USA)
09:40–10:00 Bringing it all Together for the HCP and Patient: Dexcom G6 and Dexcom Clarity Feature Utilization
Keri Leone (USA)
CHAIRS: María Asunción Martínez-Brocca (Spain) and Rolf Hinzmann (Germany)
Friday, 21 February 2020 | 10:30- 12:00 | Auditorium A
10:30 – 10:40 Introduction
10:40 – 11:05 Optimising therapy with an open ecosystem: United we manage diabetes better
Julien Boisdron (Switzerland)
11:05 – 11:25 Improving patients' and health-economic outcomes with integrated Personalised Diabetes Management
Wendelin Schramm (Germany)
11:25 – 11:45 Insulin delivery today and in the future – opportunities and challenges
Nick Oliver (UK)
11:45 – 12:00 Discussion and closing
CHAIR: Tadej Battelino (Slovenia)
Friday 21 February 2020 | 15:00–16:30 | Auditorium A
15:00–15:05 WELCOME AND INTRODUCTION
Tadej Battelino (Slovenia)
15:05–15:25 A NEED FOR REAL CHANGE: UNMET NEEDS IN CARE AND THERAPEUTIC SOLUTIONS
Pratik Choudhary (UK)
15:25–15:45 MADE TO MEASURE: THE FITNESS OF GLYCAEMIC METRICS IN THE MONITORING ERA
Richard Bergenstal (USA)
15:45–16:05 INTEGRATED HEALTHCARE ECOSYSTEMS IN THE ‘BIG DATA’ ERA
David Kerr (USA)
16:05–16:25 A STEP TOWARDS A PERSONALISED FUTURE: SIGNALS, MODELS AND PRECISE CONTROL
Boris Kovatchev (USA)
16:25–16:30 MEETING CLOSE
SYMPOSIUM IS ORGANIZED AND SUPPORTED BY Lilly
CHAIR: Howard Wolpert (USA)
Friday, 21 February 2020, | 16:40-18:00 | Madrid Hall
16:40 – 16:45 Welcome and Introduction
Howard Wolpert (USA)
16:45 – 17:05 Insulin Dosing Metrics
David Rodbard (USA)
17:05 – 17:20 The Behavioral Side of Insulin Data
William Polonsky (USA)
17:20 – 17:35 The Power of Connected Pen Data
Jennal Johnson (USA)
17:35 – 17:55 Panel Discussion and Questions & Answers
All faculty
17:55 – 18:00 Closing Remarks
Howard Wolpert (USA)